Over 90 percent of people with Huntington’s disease develop chorea. Learn about FDA-approved VMAT2 inhibitors, off-label medications, and lifestyle strategies to manage involuntary movements.
SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study about INGREZZA® (valbenazine) capsules ...
Everyday Health on MSN
Adaptive devices to maintain independence with Huntington’s disease
These tools and expert tips can help people with Huntington’s disease maintain independence in mobility, home safety, ...
SAN DIEGO, Aug. 18, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA® (valbenazine) capsules for the ...
Credit: Getty Images. Valbenazine 40mg achieved greater placebo-adjusted improvement in chorea as early as week 2 and sustained greater efficacy through week 12 compared with placebo. Valbenazine ...
Credit: Neurocrine Biosciences. Nearly half of patients receiving Ingrezza saw a more than 40% reduction in Huntington disease chorea severity by the end of the treatment period. The Food and Drug ...
Please provide your email address to receive an email when new articles are posted on . The new once-daily tablet strength doses are 30 mg, 36 mg, 42 mg and 48 mg. Symptom improvement in tardive ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Ingrezza sprinkle capsules to treat adults with Huntington’s disease chorea or tardive ...
A new drug was approved for Huntington's chorea in 2023, and novel insights about Huntington's disease emerged in new research. Valbenazine for Huntington's Chorea In August, the FDA expanded the ...
Huntington’s disease can drain energy in many ways. Pacing yourself, eating enough, staying safely active, getting good sleep, and asking your care team about treatable symptoms can help.
SAN DIEGO, Sept. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT ®-HD2 study of INGREZZA ® (valbenazine) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results